Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorVELLOSO, Elvira Deolinda Rodrigues Pereira
dc.contributor.authorMAGALHÃES, Silvia Maria Meira
dc.contributor.authorCHAUFFAILLE, Maria de Lourdes Lopes Ferrari
dc.contributor.authorBUZZINI, Renata
dc.contributor.authorBERNARDO, Wanderley Marques
dc.identifier.citationHEMATOLOGY, TRANSFUSION AND CELL THERAPY, v.40, n.3, p.267-273, 2018
dc.publisherAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.relation.ispartofHematology, Transfusion and Cell Therapy
dc.titlePart 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
dc.rights.holderCopyright Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.subject.wosMedicine, General & Internal
dc.type.categoryoriginal article
dc.type.versionpublishedVersionÃES, Silvia Maria Meira:Universidade Federal do Ceará, Brazil, Maria de Lourdes Lopes Ferrari:Grupo Fleury, Brazil; Universidade Federal de São Paulo, Brazil, Renata:Associação Médica Brasileira, Brazil
hcfmusp.relation.referenceBalleari E, 2006, ANN HEMATOL, V85, P174, DOI 10.1007/s00277-005-0044-6
hcfmusp.relation.referenceBalleari E, 2011, LEUKEMIA RES, V35, P1472, DOI 10.1016/j.leukres.2011.05.025
hcfmusp.relation.referenceCastelli R, 2014, ANN HEMATOL, V93, P1523, DOI 10.1007/s00277-014-2070-8
hcfmusp.relation.referenceChung CY, 2012, ANTICANCER RES, V32, P3415
hcfmusp.relation.referenceFili C, 2013, CLIN CANCER RES, V19, P3297, DOI 10.1158/1078-0432.CCR-12-3540
hcfmusp.relation.referenceGarcia-Manero G, 2013, J CLIN ONCOL, V31, P2548, DOI 10.1200/JCO.2012.44.6823
hcfmusp.relation.referenceGattermann N, 2012, EUR J HAEMATOL, V88, P260, DOI 10.1111/j.1600-0609.2011.01726.x
hcfmusp.relation.referenceGoldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018
hcfmusp.relation.referenceGreenberg PL, 2013, LEUKEMIA LYMPHOMA, V54, P321, DOI 10.3109/10428194.2012.713477
hcfmusp.relation.referenceHata T, 2013, INT J HEMATOL, V98, P687, DOI 10.1007/s12185-013-1468-8
hcfmusp.relation.referenceHellstrom-Lindberg E, 2003, BRIT J HAEMATOL, V120, P1037, DOI 10.1046/j.1365-2141.2003.04153.x
hcfmusp.relation.referenceHellstromLindberg E, 1997, BRIT J HAEMATOL, V99, P344, DOI 10.1046/j.1365-2141.1997.4013211.x
hcfmusp.relation.referenceKelaidi C, 2013, ANN HEMATOL, V92, P621, DOI 10.1007/s00277-013-1686-4
hcfmusp.relation.referenceKim IH, 2015, TRANSFUSION, V55, P1613, DOI 10.1111/trf.13036
hcfmusp.relation.referenceLi X, 2012, AM J HEMATOL, V87, P26, DOI 10.1002/ajh.22184
hcfmusp.relation.referenceLian XY, 2016, PLoS ONE, V11
hcfmusp.relation.referenceList A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668
hcfmusp.relation.referenceList AF, 2012, J CLIN ONCOL, V30, P2134, DOI 10.1200/JCO.2010.34.1222
hcfmusp.relation.referenceMainous AG, 2014, BRIT J HAEMATOL, V167, P720, DOI 10.1111/bjh.13053
hcfmusp.relation.referenceMannone L, 2006, BRIT J HAEMATOL, V133, P513, DOI 10.1111/j.1365-2141.2006.06070.x
hcfmusp.relation.referenceMeerpohl JJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007461.pub3
hcfmusp.relation.referenceMoyo V, 2008, ANN HEMATOL, V87, P527, DOI 10.1007/s00277-008-0450-7
hcfmusp.relation.referenceMusto P, 2005, BRIT J HAEMATOL, V128, P204, DOI 10.1111/j.1365-2141.2004.05288.x
hcfmusp.relation.referenceMusto P, 2010, LEUKEMIA RES, V34, P981, DOI 10.1016/j.leukres.2009.10.022
hcfmusp.relation.referenceMusto P, 2010, CANCER-AM CANCER SOC, V116, P1485, DOI 10.1002/cncr.24894
hcfmusp.relation.referenceOliva EN, 2017, LANCET HAEMATOL, V4, pE127, DOI 10.1016/S2352-3026(17)30012-1
hcfmusp.relation.referencePark S, 2016, BRIT J HAEMATOL, V174, P730, DOI 10.1111/bjh.14116
hcfmusp.relation.referenceRaza A, 2008, BLOOD, V111, P86, DOI 10.1182/blood-2007-01-068833
hcfmusp.relation.referenceSanchez-Garcia J, 2015, LEUKEMIA RES, V39, pS59, DOI 10.1016/S0145-2126(15)30115-6
hcfmusp.relation.referenceSantini V, 2016, J CLIN ONCOL, V34, P2988, DOI 10.1200/JCO.2015.66.0118
hcfmusp.relation.referenceTobiasson M, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.8
hcfmusp.relation.referenceToma A, 2016, LEUKEMIA, V30, P897, DOI 10.1038/leu.2015.296
hcfmusp.relation.referenceLevels of Evidence and Grades of Recommendations, Oxford Centre for Evidence Based Medicine
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Files in This Item:
File Description SizeFormat 
art_VELLOSO_Part_3_Myelodysplastic_syndromes—Treatment_of_lowrisk_patients_without_2018.PDFpublishedVersion (English)336.08 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.